CAV1 and ovarian carcinoma: This aspect could represent an advantage for the application of CD-NSs, since CAV-1 is down-regulated in the vast majority of ovarian carcinomas 60, and its expression greatly change in different type of cancers, depending on tumor staging and the tumor microenvironment 61.